OvaScience Expands Senior Team with Two New Key Hires

CAMBRIDGE, Mass.--()--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today two new positions that support OvaScience’s expanding international operations. John Eisel has joined the Company as Executive Vice President of Global Site Operations, and Gabriel M. Cohn, M.D., has joined as Head of Medical Affairs and Translational Medicine.

“OvaScience’s patient-driven mission and success in developing new fertility treatment options for women have enabled us to continue to attract top talent,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “John’s experience in leading strategic operations and logistics will help us as we continue building the global network of IVF clinics offering our fertility treatments. We also welcome the contributions that Gabe will bring as an OB/GYN, an expert in reproductive medicine and an experienced leader in developing therapeutic franchises.”

Mr. Eisel joins from InnerWorkings LLC, where he served as Chief Operating Officer since 2011. Prior to that, he was Divisional Vice President of Strategic Operations, Pharmacy Services for Walgreens, where he designed and led operations strategy for the more than $40 billion pharmacy business. He also held roles of increasing responsibility at McKinsey & Company, including serving as Associate Principal. Mr. Eisel began his career at PricewaterhouseCoopers, serving as a Senior Associate in Financial Advisory Services. Mr. Eisel is a Certified Public Accountant and holds a B.S. in Accountancy from the University of Illinois at Urbana-Champaign and an M.B.A. from Northwestern’s Kellogg School of Business.

Dr. Cohn is a Board-certified OB/GYN and Clinical Geneticist who previously served as the Chief of the Division of Clinical and Reproductive Genetics Department at Baystate Medical Center and the Director of Reproductive Genetics, Division of Maternal Fetal Medicine at SUNY Health Science Center (HSC) at Syracuse. Dr. Cohn joins OvaScience from Shire, where he held roles that included Medical Director and Interim Medical Lead for the Gaucher Disease Franchise and the Senior Medical Director of Clinical Sciences. In these roles, he was responsible for activities such as medical affairs’ educational programs, publication strategy, key opinion leader engagement, patient registry strategy and asset evaluation. Dr. Cohn holds an M.D. from SUNY HSC at Syracuse, School of Medicine and an M.B.A. from the Isenberg School of Management, University of Massachusetts. He completed his OB/GYN residency at SUNY HSC at Syracuse and his clinical genetics fellowship at the National Institutes of Health.

In conjunction with Mr. Eisel’s appointment and the previously announced appointment of Ravi Mehrotra, Ph.D., to Chief Corporate Development Officer, the Company reported inducement option grants to both executives in accordance with NASDAQ Listing Rule 5635(c)(4). The awards were approved by the Board on June 4, 2015 as an inducement material to both executives entering into employment with the Company. Mr. Eisel’s and Dr. Mehrotra’s inducement grants consisted of an option to purchase up to 350,000 and 311,800 shares of common stock, respectively. The options will be exercisable at a price of $36.19 per share (the closing price on the date of grant) and will vest as to 25% of the shares on June 3, 2016 for Mr. Eisel and on May 18, 2016 for Dr. Mehrotra and as to an additional 6.25% of the shares per quarter thereafter, provided that each remains employed by OvaScience on their vesting dates.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the commercial ramp up of the AUGMENT treatment, which we expect will depend upon the successful transition of ACE clinics to commercial operations, the addition of new ACE clinics, and the results from ACE clinic experience as they become available; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

###

Contacts

OvaScience
Investors
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
tmcneely@ovascience.com
or
Media
Cara Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com

Contacts

OvaScience
Investors
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
tmcneely@ovascience.com
or
Media
Cara Mayfield, 617-714-9638
Director, Corporate Communications
cmayfield@ovascience.com